Drug – bio-affecting and body treating compositions – Designated organic nonactive ingredient containing other... – Aftertreated solid synthetic organic polymer
Reexamination Certificate
2011-08-30
2011-08-30
Ketter, Jim (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic nonactive ingredient containing other...
Aftertreated solid synthetic organic polymer
C524S557000, C435S458000
Reexamination Certificate
active
08008355
ABSTRACT:
The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
REFERENCES:
patent: 4587044 (1986-05-01), Miller et al.
patent: 4904582 (1990-02-01), Tullis
patent: 5138045 (1992-08-01), Cook et al.
patent: 5547932 (1996-08-01), Curiel et al.
patent: 5574142 (1996-11-01), Meyer et al.
patent: 5994316 (1999-11-01), Lollo et al.
patent: 5994517 (1999-11-01), Ts'o et al.
patent: 6020457 (2000-02-01), Klimash et al.
patent: 6300317 (2001-10-01), Szoka et al.
patent: 6300319 (2001-10-01), Manoharan
patent: 6312727 (2001-11-01), Schacht et al.
patent: 6590071 (2003-07-01), Shen et al.
patent: 7098030 (2006-08-01), Rozema et al.
patent: 2002/0082198 (2002-06-01), Sakurai et al.
patent: 2003/0072794 (2003-04-01), Boulikas
patent: 2003/0157030 (2003-08-01), Davis et al.
patent: 2003/0220289 (2003-11-01), Monahan et al.
patent: 2004/0110296 (2004-06-01), Vargeese et al.
patent: 2004/0156909 (2004-08-01), Rozema et al.
patent: 2004/0162260 (2004-08-01), Rozema et al.
patent: 2004/0204377 (2004-10-01), Rana
patent: 2004/0249178 (2004-12-01), Vargeese et al.
patent: 2005/0008617 (2005-01-01), Chen et al.
patent: 2005/0037496 (2005-02-01), Rozema et al.
patent: 2005/0112470 (2005-05-01), Taylor et al.
patent: 2006/0040882 (2006-02-01), Chen et al.
patent: 2006/0134189 (2006-06-01), MacLachlan et al.
patent: 2006/0166234 (2006-07-01), Robertson et al.
patent: 2006/0240092 (2006-10-01), Breitenkamp et al.
patent: 2006/0247429 (2006-11-01), McSwiggan et al.
patent: 2007/0003609 (2007-01-01), Collin-Djangone et al.
patent: 2007/0041932 (2007-02-01), Jeong et al.
Blattler WA et al. “New Heterobifunctional Protein Cross-Linking Reagent That Forms an Acid Labile Link.” Biochemistry. 1985. vol. 24, p. 1517-1524.
Boussif O et al. “A Versatile Vector for Gene and Oligonucleotide Transfer Into Cells in Culture and In Vivo: Polyethylenimine.” Biochemistry, 1995, vol. 92, pp. 7297-7301.
Dash PR et al. “Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin.” J Biol Chem. 2000; vol. 275, No. 6, p. 3793-3802.
Diebold et al., “Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells,” Journal of Biological Chemistry, 1999; vol. 274, p. 19087-19094.
Ferruti, P et al. “Amphoteric Linear Poly(amido-amine)s as Endosomolytic Polymers: Correlation between Physicochemical and Biological Properties” Macromolecules; 2000; vol. 33, No. 21, p. 7793-7800.
Dixon HBF et al. Reversible Blocking of Amino Groups with Citraconic Anhydride. Biochemical Journal. 1968. vol. 109, p. 312-313.
Garman AJ et al. The Preparation and Properties of Novel Reversible Polymer-Protein Conjugates. FEBS Letters. 1987. vol. 223 No. 2 p. 364-365.
Greenwald RB et al. “Poly(ethylene glycol) Conjugated Drugs and Prodrugs: A Comprehensive Review.” Critical Reviews in Therapeutic Drug Carrier Systems 2000. vol. 17, p. 101-161.
Kirby AJ et al. Structure and Efficiency in Intramolecular and Enzymic Catalysis. Catalysis of Amide Hydrolysis by the Carboxy-group of Substituted Malearmc Acids. J Chem Soc Perkin 1972, vol. 11 p. 1206-1214.
Kishore K et al. “Polymers Containing Disulfide, Tetrasulfide, Diselenide and Ditelluride Linkages in the Main Chain.” Advances in Polymer Sciences; 1995, vol. 121, pp. 83-92.
Manoharan M et al. “Cholic Acid-Oligonucleotide Conjugates for Antisense Applications”, Bioorg. Med. Chem. Letts., 1994, vol. 4, p. 1053-1060.
Manoharan M et al. “Oligonucleotide conjugates: Alternation of the Pharmacokinetic Properties of Antisense Agents”, Nucleosides & Nucleotides, 1995, vol. 14, p. 969-973.
Kratz F et al. “Drug-Polymer Conjugates Containing Acid-Cleavable Bonds.” Critical Reviews in Therapeutic Drug Carrier Systems; 1999, vol. 16, No. 3, pp. 245-289.
Legendre J-Y et al. “Delivery of Plasmid DNA Into Mammalian Cell Lines Using pH-Sensitive Liposomes: Comparison with Cationic Liposomes.” Pharmaceutical Research; 1992, vol. 9, No. 10, pp. 1235-1242.
Murthy S. et al. “Design and synthesis of pH-responsive polymeric carriers that target uptake and enhance the intracellular delivery of oligonucleotides” Journal of Controlled Release, 2003; vol. 89, p. 356-374.
Oupicky D et al. “Development of Long-circulating Polyelectrolyte Complexes for Systemic Delivery of Genes” Journal of Drug Targeting, 2002; vol. 10, No. 2, p. 93-98.
Murthy N et al. “The Design and Synthesis of Polymers for Eukaryotic Membrane Disruption.” Journal of Controlled Release; 1999, vol. 61, p. 137-143.
Naganawa A et al. Synthetic Studies on Tautomycin Synthesis of 2,3-Disubstituted Maleic Anhydride Segment. Tetrahedron 1994. vol. 50:8969.
Saito G et al. “Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities” Advanced Drug Delivery Reviews 2003; vol. 55, p. 199-215.
Nieto MA, et al. Effects of Temperature and pH on the Regeneration of the Amino Groups of Ovalbumin After Modification with Citraconic and Dimethylmaleic Anhydrides. Biochimica et Biophysica Acta. 1983, vol. 749, p. 204-210.
Plank C et al. “Application of Membrane-Active Peptides for Drug and Gene Delivery Across Cellular Membranes.” Advanced Drug Delivery Reviews, 1998, vol. 34, pp. 21-35.
Senoir JH et al. “Interaction of Positively-Charged Liposomes with Blood: Implications for Their Application In Vivo.” Biochemica et Biophysica Acta; 1991, vol. 1070, pp. 173-179.
Van De Wetering P et al. “Copolymers of 2-(Dimethylamino)Ethyl Methacrylate with Ethoxytriethylene Glycol Methacrylate of N-Vinyl-Pyrrolidone as Gene Transfer Agents.” Journal of Controlled Release; 2000, vol. 64, p. 193-203.
Zhou X et al. “Lipophilic Polylysines Mediate Efficient DNA Transfection in Mammalian Cells.” Biochemica et Biophysica Acta; 1991, vol. 1065, pp. 8-14.
Li W et al. “Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery” Journal of Gene Medicine 2005; vol. 7, No. 1, p. 67-79.
Wu J et al. “Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications.” Front Biosci. 2002;vol. 7, p. 717-725.
Xu P “Targeted Charge-Reversal Nanoparticles for Nuclear Drug Delivery” Angew Chem Int Ed 2006; vol. 46, p. 4999-5002.
Hagstrom James E.
Higgs Lori
Monahan Sean D.
Rozema David B.
Wakefield Darren H.
Ekena Kirk
Ketter Jim
Roche Madison Inc.
LandOfFree
Endosomolytic poly(vinyl ether) polymers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endosomolytic poly(vinyl ether) polymers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endosomolytic poly(vinyl ether) polymers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2671992